key: cord-0983909-aqqv8wnx
authors: Sedegah, Martha; Porter, Chad; Hollingdale, Michael R.; Ganeshan, Harini; Huang, Jun; Goforth, Carl W.; Belmonte, Maria; Belmonte, Arnel; Weir, Dawn L.; Lizewski, Rhonda A.; Lizewski, Stephen E.; Sealfon, Stuart C.; Jani, Vihasi; Cheng, Ying; Inoue, Sandra; Velasco, Rachael; Villasante, Eileen; Sun, Peifang; Letizia, Andrew
title: CHARM: COVID-19 Health Action Response for Marines – association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test
date: 2021-12-14
journal: bioRxiv
DOI: 10.1101/2021.12.13.472352
sha: d7248a23353b45fd2051b85fae6f1be2402f36cf
doc_id: 983909
cord_uid: aqqv8wnx

SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- and Class II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) and membrane (M) proteins and others. This prospective COVID-19 Health Action Response for Marines (CHARM) study enabled assessment of T cell responses in symptomatic and asymptomatic SARS-CoV-2 infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly and then bimonthly for the next 6 weeks. Study participants who tested positive by qPCR SARS-CoV-2 test were asked to enroll in an immune response sub-study. FluoroSpot interferon-gamma (IFN-γ) and IL2 responses following qPCR-confirmed infection at enrollment (day 0), day 7 and 14 and more than 28 days later were measured using pools of 17mer peptides covering S, N, and M proteins, or CD4+CD8 peptide pools containing predicted epitopes from multiple SARS-CoV-2 antigens. Among 124 asymptomatic and 105 symptomatic participants, SARS-CoV-2 infection generated IFN-γ responses to the S, N and M proteins that persisted longer in asymptomatic cases. IFN-γ responses were significantly (p=0.001) more frequent to the N pool (51.4%) than the M pool (18.9%) among asymptomatic subjects; however, the difference was not statistically significant (p=0.06) for symptomatic subjects (N pool: 44.4%; M pool: 25.9%). In asymptomatic participants IFN-γ responders to the CD4+CD8 pool responded more frequently to the S pool (55.6%) and N pool (57.1%), than the M pool (7.1%), but symptomatic participants, IFN-γ responses were more frequent to the S pool (75.0%) than N pool (33.3%) and M pool (33.3%). The frequencies of IFN-γ responses to the S and N+M pools peaked 7 days after the positive qPCR test among asymptomatic (S pool: 22.2%; N+M pool: 28.7%) and symptomatic (S pool: 15.3%; N+M pool 21.9%) participants and dropped by >28 days. Magnitudes of post-infection IFN-γ and IL2 responses to the N+M pool were significantly correlated with IFN-γ and IL2 responses to the N and M pools. These data further support the central role of Th1-biased cell mediated immunity IFN-γ and IL2 responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-based COVID-19 vaccines that include the N and S proteins.

IFN-γ and IL2 responses to the N+M pool were significantly correlated with responses to the N and M pools. 49 These data further support the central role of Th 1 -biased cell mediated immunity responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-51 based COVID-19 vaccines that include the N and S proteins. IFN-γ responses to the N+M pool were significantly more frequent than to the S pool (p=0.03), 210 whereas there was no difference in IL2 responses (Table 1B) . The responses to the S pool (63.3%) were higher than the N (47.8%) or M (17.4%) pools.

However, in asymptomatic participants IFN-γ responses to S and N pools were similar (55.6% 225 and 57.1%, respectively) and higher than to the M pool (7.1%) (Table 3) , whereas in 226 symptomatic participants, IFN-γ responses to the S pool were higher (75.0%) than to the N and 227 M pools (33.3% each) (Table 3 ). This suggests that among asymptomatic participants in this 228 study with IFN-γ responses to the CD4+CD8 pool, responses are generally directed to epitopes 229 within the S pool and N pool and not within the M pool, whereas in symptomatic participants, 230 IFN-γ to the CD4+CD8+ responses are more frequent to epitopes within the S protein than the N 231 protein. (Table 3) . However, we only assessed asymptomatic and symptomatic participants with mild disease who 279 were all treated as outpatients. Therefore, we cannot extrapolate our findings to other studies 280 using patients with severe disease that suggested lung-homing T cells may contribute to 281 immunopathology, while non-suppressive SARS-CoV-2-specific T cell responses may limit 282 pathogenesis and promote recovery from severe .

Early induction of IFN-γ SARS-CoV-2-specific T cell responses to the S protein has been 285 previously associated with mild disease and accelerated viral clearance [28, 30] accounting for over 80% of the response, confirming an earlier more limited study [9] , and 296 CD4+ and CD8+ responses were highly correlated. Our study extends these findings to include 297 the role of the N protein and CD4+CD8+ T cell responses. A major concern of current antibody-based vaccines are mutations in the S protein that affect 310 sequences recognized by vaccine-induced neutralizing antibodies [45] [46] [47] [48] [49] [50] [51] . However, it has been 311 suggested that it is highly unlikely that SARS-CoV-2 mutations would affect T cell immunity as 312 so many SARS-CoV-2 epitopes are distributed throughout virus [52, 53] . However, mutations in 313 new variants, including the Delta variant, significantly reduced T cell responses to epitope 314 peptides in convalescent and vaccinated subjects [51] , and in in vitro binding assays [54] . The 315 genetic HLA-restriction of T cell responses associated with disease outcomes would greatly 316 advance our understanding of the relative importance of predicted epitopes including those used 317 in this study, and whether newly emerging variants of concern carry mutations within these 318 protective epitopes. For example, the L452R mutation contributes to evasion of HLA-A24-319 mediated cellular immunity [55] . 

Comparison of the frequencies and magnitudes of responses are shown in Figure S1 and Figure   655 S2. The numbers and percent positive of asymptomatic and symptomatic participants with positive and combined in the CD4+CD8 peptide pool. 

Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

NetMHCpan-4.1 and NetMHCIIpan-4.0: 418 improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration 419 of MS MHC eluted ligand data

SARS-CoV-2 human T cell 422 epitopes: Adaptive immune response against COVID-19

CD8(+) T 426 cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective 427 seasonal coronaviruses

The 430 presentation of SARS-CoV-2 peptides by the common HLA-A( *)02:01 molecule. iScience

mRNA vaccination boosts 557 cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Prior SARS-CoV-2 560 infection rescues B and T cell responses to variants after first vaccine dose

The potential clinical 564 utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses

T cell and 568 antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 569 clinical trial

Escape of SARS-CoV-2 501Y.V2 from 572 neutralization by convalescent plasma

Resistance of SARS-CoV-2 575 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

to mRNA vaccine-elicited antibodies

SARS-CoV-2 582 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Epub 2021/07/17

SARS-CoV-2 variants B.1.351 586 and P.1 escape from neutralizing antibodies

CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Profiling CD8(+) T cell epitopes of COVID-19 593 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants

Targets of T Cell 597 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Epub 2020/05/31

Adaptive immunity to SARS-CoV-2 and COVID-19

PubMed PMID: 33497610; PubMed Central PMCID: 602 PMCPMC7803150 Epitogenesis, Gilead, and Avalia. S.C. is a consultant for Avalia. LJI has filed for patent 603 protection for various aspects of T cell epitope and vaccine design work

SARS-CoV-2 605 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses

SARS-CoV-2 spike L452R 609 variant evades cellular immunity and increases infectivity

-2 T cell epitopes in unexposed humans

Is the "Common Cold" Our Greatest Ally in the 616

Battle Against SARS-CoV-2?

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Epub 2020/07/09

The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine 622

Epub 2020/06/18

Immunization with RBD-P2 and N 625 protects against SARS-CoV-2 in nonhuman primates

Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity

Rational Design of SARS-CoV-2 Spike Glycoproteins To 631

Epub 2020/08/21

Immunoinformatic Analysis of SARS-CoV-2

Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets

Figure 1. Participant Flow: times of FluoroSpot assays relative to the first positive PCR test

When qPCR positive, the participant was transferred to the immune 694 response subgroup within 48-96 hours (7d*) and tested by qPCR biweekly and bimonthly 695 thereafter. PBMCs were isolated (red arrows) prior to the initial qPCR (at enrollment, T0), and 696 once positive at ¾ days 7 days (grouped into T7), 10/11 days (grouped into T14), and greater 697 than 28 days

Figure 2. Magnitudes of IFN-γ and IL2 responses of asymptomatic, symptomatic 700 participants before and after infection, and healthy uninfected participants

Pre-infection (Pre) and maximum IFN-γ and IL2 responses post-infection (Post) to S, N+M, and 704 CD4+CD8 peptide pools of asymptomatic and symptomatic participants, and healthy uninfected 705 participants (Pre = baseline and Post = post-baseline)

Correlations of the magnitude of IFN-γ and IL2 responses post-infection to the N 709 and M pools with IFN-γ and IL2 responses to the N+M pool

The maximum IFN-γ and IL2 responses post-infection to the N and M pools were compared to 712 those to the mixture of N+M pool in matched participants by Spearman Rank Correlations

Correlations of the magnitude of IFN-γ responses post-infection to the S, N, and 715 N+M pools with IFN-γ responses to the CD4+CD8 pool

The magnitudes of IFN-γ responses to the CD4+CD8 pool were compared to the magnitudes of 718

Using Spearman's ranked correlations

 AGL, YG, SV, CG, DLW, HWC, NAK, CAB, DE, M-CG, WDG, FJ, RAL, SEL, JM, NM, CMM, PB, SM, VDN, EN,  462  CKP, ESA, AS-S, MS, VAS, MT, PS, RPT,